Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.98 |
| ▸ | CNR1 | P21554 | 5/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5624470 | 0.99 | CNR2 (1.00) | CNR2CNR1SMN1; SMN2TSHRMAPT | |
| SCHEMBL5623492 | 0.90 | CNR2 (1.00) | CNR2CNR1SMN1; SMN2TSHRMAPT | |
| SCHEMBL14485527 | 0.86 | CNR1 (0.78) | CNR2CNR1SMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL14485159 | 0.86 | CNR1 (0.78) | CNR2CNR1SMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL5626848 | 0.86 | CNR2 (0.98) | CNR2CNR1SMN1; SMN2TSHRTP53 | |
| SCHEMBL5625757 | 0.85 | CNR2 (1.00) | CNR2CNR1SMN1; SMN2TSHRTP53 | |
| SCHEMBL14367344 | 0.83 | CNR2 (0.78) | CNR2CNR1SMN1; SMN2TSHRMAPT | |
| SCHEMBL5623628 | 0.81 | CNR2 (1.00) | CNR2CNR1SMN1; SMN2TSHRMAPT | |
| SCHEMBL5623378 | 0.81 | CNR2 (1.00) | CNR2CNR1SMN1; SMN2TSHRMAPT | |
| SCHEMBL1003299 | 0.79 | MAPK1 (0.79) | CNR2CNR1SMN1; SMN2ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7297796-B2 | Sulfamoyl benzamide derivatives and methods of their use | ADOLOR CORPORATION (US) | 2007-11-20 | — | — | US | claimed |
| WO-2006044645-A2 | SULFAMOYL BENZAMIDES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2006-04-27 | — | — | WO | claimed |
| US-20060079557-A1 | Sulfamoyl benzamide derivatives and methods of their use | ADOLOR CORPORATION (US) | 2006-04-13 | — | — | US | claimed |
| US-7297796-B2 | Sulfamoyl benzamide derivatives and methods of their use | ADOLOR CORPORATION (US) | 2007-11-20 | — | — | US | disclosed |
| US-7297796-B2 | Sulfamoyl benzamide derivatives and methods of their use | ADOLOR CORPORATION (US) | 2007-11-20 | — | — | US | disclosed |
| US-7297796-B2 | Sulfamoyl benzamide derivatives and methods of their use | ADOLOR CORPORATION (US) | 2007-11-20 | — | — | US | disclosed |
| WO-2006044645-A2 | SULFAMOYL BENZAMIDES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060079557-A1 | Sulfamoyl benzamide derivatives and methods of their use | ADOLOR CORPORATION (US) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079557-A1 | Sulfamoyl benzamide derivatives and methods of their use | CNR2, TRPV1, CNR1 | CNR2 1/4885CNR1 3/4885SMN1; SMN2 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.